WebApr 10, 2024 · Mainz Biomed Provides Full Year 2024 Financial Results ColoAlert Revenue Increases 130% Year over Year Year End Cash Balance of $17.1 Million . BERKELEY, … WebApr 10, 2024 · Year End Cash Balance of $17.1 Million. BERKELEY, US – MAINZ, Germany – April 10, 2024 — Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today financial results for the fiscal year ended December 31, 2024.
News - Mainz Biomed
WebApr 10, 2024 · Year End Cash Balance of $17.1 Million. BERKELEY, Calif. and MAINZ, Germany, April 10, 2024 (GLOBE NEWSWIRE) — Mainz Biomed N.V. MYNZ (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today financial results for the fiscal year ended … WebMar 29, 2024 · BERKELEY, US MAINZ, Germany March 29, 2024 Mainz Biomed NV (NASDAQ:MYNZ) (Mainz Biomed or the Company), a molecular genetics diagnostic company specializing in the early detection of cancer ... biotronic maternity
Mainz Biomed Provides Full Year 2024 Financial Results
WebAug 16, 2024 · About Mainz Biomed N.V. Mainz Biomed develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The Company’s flagship product is ColoAlert, an accurate, non ... WebApr 10, 2024 · Year End Cash Balance of $17.1 Million. BERKELEY, US - MAINZ, Germany - April 10, 2024 - Mainz Biomed N.V. (NASDAQ:MYNZ) ("Mainz Biomed" or the … WebApr 10, 2024 · Year End Cash Balance of $17.1 Million. BERKELEY, Calif. and MAINZ, Germany, April 10, 2024 (GLOBE NEWSWIRE) — Mainz Biomed N.V. MYNZ (“Mainz … dale beatty purple heart homes